Advisory Panel Recommends FDA Approve Marketing Authorization For Novel Breast Cancer Treatment

The US FDA’s advisory panel on general and plastic surgery devices voted in favor of agency approval for a novel medical device for treating early stage, low-risk breast cancer as a potential alternative to lumpectomy. The agency is expected to make its decision on the device early next year.

More from Medtech Insight

More from Regulation